Efficacy and toxicity of conventionally fractionated pelvic radiation with a hypofractionated simultaneous versus conventionally fractionated sequential boost for patients with high-risk prostate cancer

Acta Oncologica

Volumn 52, Issue 6, 2013, Pages 1181-1188

  Mcdonald, Andrew M ^a   Jacob, Rojymon ^a   Dobelbower, Michael C ^a   Kim, Robert Y ^a   Fiveash, John B ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABLATION THERAPY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; COMPARATIVE STUDY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RECTUM DISEASE; UROGENITAL TRACT DISEASE; ADJUVANT CHEMOTHERAPY; ANDROGEN DEPRIVATION THERAPY; CANCER HORMONE THERAPY; CANCER STAGING; CLINICAL EFFECTIVENESS; CONVENTIONALLY FRACTIONATED SEQUENTIAL BOOST; DIARRHEA; HEMATURIA; HYPOFRACTIONATED SIMULTANEOUS INTEGRATED BOOST; IMAGE GUIDED RADIOTHERAPY; INTERMETHOD COMPARISON; PROSTATE; RADIATION CYSTITIS; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RECTAL PAIN; RECTAL TOXICITY; RECTUM HEMORRHAGE; TREATMENT DURATION; TREATMENT RESPONSE; URETHRA STENOSIS; URINARY TOXICITY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DOSE FRACTIONATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; RISK;

BICALUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

EID: 84880280066     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2012.748987     Document Type: Article

References (21)

1. Pollack A, Hanlon A, Horwitz E, Feigenberg S, Konski A, Movsas B, et al. Dosimetry and preliminary acute toxicity in the fi rst 100 men treated for prostate cancer on a randomized hypofractionated dose escalation trial. Int J Rad Oncol Biol Phys 2006; 64: 518-52.
2. Pahlajani N, Ruth K, Buyyounouski M, Chen D, Horwitz E, Hanks G, et al. Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate. Int J Rad Oncol Biol Phys 2012; 82: 1949-56.
3. Leborgne F, Fowler J, Leborgne J, Mezzera J. L ater outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer. Int J Rad Oncol Biol Phys 2012; 82: 1200-7.
4. Shaffer R, Pickles T, Lee R, Moiseenko V. D eriving prostate alpha-beta ratio using carefully matched groups, long follow-up and the phoenix defi nition of biochemical failure. Int J Rad Oncol Biol Phys 2011; 79: 1029-36.
5. Lawton C, DeSilvio M, Roach M, Uhl V, Kirsch R, Seider M, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Rad Oncol Biol Phys 2007; 69: 646-55.
6. Adkison J, McHaffi e D, Bentzen S, Patel R, Khuntia D, Petereit D, et al. Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. Int J Rad Oncol Biol Phys 2012; 82: 184-90.
7. Quon H, Cheung P, Loblaw D, Morton G, Pang G, Szumacher E, et al. Hypofractionated concominant intensity-modulated radiotherapy boost for high-risk prostate cancer: Late toxicity. Int J Rad Oncol Biol Phys 2012; 82: 898-905.
8. Pollack A, Walker G, Buyyounouski M, Horwitz E, Price R, Feigenberg S, et al. Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer. Int J Rad Oncol Biol Phys 2011; 81: S1.
9. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. US Department of Health and Human Services; 2009.
10. Roach M, Hanks G, Thames H, Schellhammer P, Shipley W, Sokol G, et al. Defi ning biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Rad Oncol Biol Phys 2006; 64: 965-74.
11. Roach M, DeSilvio M, Valicenti R, Grignon D, Asbell S, Lawton C, et al. Whole-pelvis, " mini-pelvis ", or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Rad Oncol Biol Phys 2006; 66: 647-53.
12. Pommier P, Chabaud S, Lagrange J, Richaud P, Lesaunier F, Le Prise E, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007; 25: 5366-73.
13. Peeters S, Heemsbergen W, Koper P, van Putten W, Slot A, Dielwart M, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24: 1990-6.
14. Jacob R, Hanlon A, Horwitz, E, Movsas B, Uzzo R, Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 2004; 100: 538-43.
15. Aizer A, Y u J, McKeon A, Decker R, Colberg J, Peschel R. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Int J Rad Oncol Biol Phys 2009; 75: 1344-9.
16. Mantini G, Tagliaferri L, Mattiucci G, Balducci M, Frascino V, Dinapoli N, et al. Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation. Int J Rad Oncol Biol Phys 2011; 81: E721-6.
17. Kupelian P, Reddy C, Carlson T, Altsman K, Willoughby T. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Rad Oncol Biol Phys 2002; 53: 904-12.
18. McCammon R, Rusthoven K, Kavanagh B, Newell S, Newman F, Raben D. Toxicity assessment of pelvic intensitymodulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer. Int J Rad Oncol Biol Phys 2009; 75: 413-20.
19. Reddy K, Nelson B, McCammon, Newell S, Newman F, Raben D. Preliminary outcomes for the treatment of intermediate-and high-risk prostate cancer patients using pelvic intensity modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate. Int J Rad Oncol Biol Phys 2010; 78: S376.
20. Arcangeli G, Fowler J, Gomellini S, Arcangeli S, Saracino B, Petrongari M, et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated threedimensional conformal radiotherapy for prostate cancer. Int J Rad Oncol Biol Phys 2011; 79: 1013-21.
21. Kupelian P, Willoughby T, Reddy C, Klein E, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Rad Oncol Biol Phys 2007; 68: 1424-30.